Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 31, 2020

View Archived Issues

GNOS-PV02 vaccine to be evaluated in patients with HCC

AI-generated compound begins phase I study in Japan for obsessive-compulsive disorder

Inovio and Beijing Advaccine collaborate to advance new vaccine against new coronavirus in China

BREEZE-AD5 phase II study of baricitinib in AD meets primary endpoint

German Medicines Agency approves phase II study of FOL-005

Kedrion Biopharma completes enrollment in phase III CARES10 study

Cerevel starts dosing volunteers in phase I study of CVL-936

First patient dosed in phase Ib study of GMI-1359 in breast cancer

FDA accepts IND application for FS-120 bispecific antibody

BBI-608 plus pembrolizumab shows encouraging antitumor activity in mCRC

Magrolimab plus cetuximab as a promising immunotherapeutic treatment regimen in CRC

Phase II study of PBI-05204 in mPDA does not meet primary endpoint

Fimbrion Therapeutics and GlaxoSmithKline describe Escherichia coli FimH inhibitors

New high affinity nerve growth factor receptor inhibitors identified at Medshine Discovery

Naltrexone prodrugs synthesized at Alkermes

Novartis patents compounds for IKZF2-dependent disease

Recordati Industria Chimica e Farmaceutica discovers P2X3 and P2X2/3 antagonists

"Confused and disorganized": Stress, identity crises part of growing up -- for organoids

RC-48-ADC shows meaningful benefit in phase I solid tumors trial

CEACAM6 levels linked to sensitivity to pelareorep in pancreatic adenocarcinoma

IRICoR, UdeM and Medigene establish collaboration on novel cancer antigens

Phase I study of Rani's orally delivered octreotide meets primary and secondary endpoints

Fuzionaire Diagnostics establishes new research collaboration in neurodegeneration

IND clearance for VistaGen's AV-101 for levodopa-induced dyskinesia in Parkinson's

Immune Response BioPharma plans IND filing for new SARS/coronavirus vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...